Chelsea Therapeutics, Inc. (CHTP) Announces First Patient Dosed In NORTHERA™ (Droxidopa) Study 401 For The Treatment Of Symptomatic NOH
12/9/2013 9:40:07 AM
CHARLOTTE, N.C., Dec. 9, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced that the first patient has been dosed in Study 401, a multi-center, multi-national, randomized, parallel-group, placebo-controlled, double-blind study of investigational drug NORTHERA™ (droxidopa), an orally active synthetic precursor of norepinephrine, being studied for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with primary autonomic failure (Parkinson's disease, multiple system atrophy and pure autonomic failure), dopamine beta hydroxylase deficiency and non-diabetic autonomic neuropathy.
Help employers find you! Check out all the jobs and post your resume.
comments powered by